Allergy Therapeutics plc (AGY) Insider Peter Jensen Buys 30,000 Shares
Allergy Therapeutics plc (LON:AGY) insider Peter Jensen bought 30,000 shares of the stock in a transaction that occurred on Thursday, September 29th. The shares were purchased at an average cost of GBX 19 ($0.25) per share, with a total value of £5,700 ($7,440.28).
Allergy Therapeutics plc (LON:AGY) opened at 20.00 on Friday. Allergy Therapeutics plc has a one year low of GBX 17.25 and a one year high of GBX 34.82. The firm’s market capitalization is GBX 111.90 million. The stock’s 50 day moving average is GBX 18.72 and its 200-day moving average is GBX 22.42.
Several equities research analysts have weighed in on AGY shares. Panmure Gordon reaffirmed a “buy” rating and issued a GBX 53 ($0.69) price target on shares of Allergy Therapeutics plc in a research note on Friday, July 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 72 ($0.94) price target on shares of Allergy Therapeutics plc in a research note on Friday, July 8th. Finally, Numis Securities Ltd started coverage on shares of Allergy Therapeutics plc in a research note on Wednesday, September 21st. They issued a “buy” rating and a GBX 37 ($0.48) price target for the company.
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.